Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01377909 · ClinicalTrials.gov registry record · Phase 1

HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity

A Phase 1 study, sponsored by Bader, Ted, M.D..

Terminated
Registry status
Phase 1
Development phase
20
Enrollment target

NCT01377909: Clinical Trial Phase 1 study, sponsored by Bader, Ted, M.D..

NCT01377909 is a Phase 1 study that was terminated before completion, run by Bader, Ted, M.D.. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01377909, a Phase 1 study, was terminated before completion, sponsored by Bader, Ted, M.D..

TERMINATED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

Objective: The goal is to improve peginterferon sensitivity in previous poor responders. "Sensitivity" here means the host's ability to kill more HCV. Design: Twenty poor responders to prior PIFN/RBV will be given 48 weeks of statin monotherapy. Veterans and civilians between the ages of 18 and 70 are eligible.

Primary Outcome

The change in hepatitis C viral load in response to one injection of peginterferon will be measured with a baseline pre-study viral load and response to an injection of peginterferon; this test will be remeasured 48 weeks later. The change in viral loads over time will be assessed statistically.

Interventions

  • DRUG statin

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2012-03
Est. Completion 2013-08
Phase Phase 1
Bader, Ted, M.D.

6 total trials

Why NCT01377909 stopped before completion

NCT01377909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 1 intervention - of which statin is the first listed.

NCT01377909 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01377909 about?

NCT01377909 is a clinical study titled "HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity". Objective: The goal is to improve peginterferon sensitivity in previous poor responders. "Sensitivity" here means the host's ability to kill more HCV. Design: Twenty poor responders to prior PIFN/RBV will be given 48 weeks of statin monotherapy. Veterans and civilians between the ages of 18 and 70 ...

What is the current status of trial NCT01377909?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-03. Estimated completion is 2013-08.

What interventions are being tested in trial NCT01377909?

The interventions under investigation include: statin (DRUG).

Who is sponsoring clinical trial NCT01377909?

This trial is sponsored by Bader, Ted, M.D., which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01377909's enrollment target sits among peer trials

20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01377909, the US trial registry maintained by the National Library of Medicine. NCT01377909 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.